Get 20M+ Full-Text Papers For Less Than $1.50/day. Subscribe now for You or Your Team.

Learn More →

P2X7: a growth-promoting receptor—implications for cancer

P2X7: a growth-promoting receptor—implications for cancer The P2X7 receptor is widely referred to as the paradigmatic cytotoxic nucleotide receptor, and is often taken as an epitome of cytotoxic receptors as a whole. However, cytotoxicity is the result of sustained pharmacological stimulation, which is likely to occur in vivo only under severe pathological conditions. Over the years, we have gathered robust experimental proof that led us to adopt an entirely different view, pointing to P2X7 as a survival/growth-promoting rather than death-inducing receptor. Evidence in favour of this role is manifold: (1) extracellular ATP and benzoyl ATP support cell proliferation in peripheral T lymphocytes via a P2X7-like receptor; (2) P2X7 transfection into several cell lines confers growth advantage; (3) HEK293 cells transfected with P2X7 show enhanced mitochondrial metabolic activity and growth; (4) lipopolysaccharide (LPS)-dependent growth arrest of microglia is mediated via P2X7 down-modulation; (5) several malignant tumours express high P2X7 levels and (6) the ATP concentration in tumour interstitium is several-fold higher than in healthy tissues, to a level in principle sufficient to activate the P2X7 receptor. The molecular basis of P2X7-mediated growth-promoting activity is poorly known, but mitochondria appear to play a central role. A deeper understanding of the role played by P2X7 in cell proliferation might provide an insight into the mechanism of normal and malignant cell growth and suggest novel anti-tumour therapies. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Purinergic Signalling Springer Journals

P2X7: a growth-promoting receptor—implications for cancer

Loading next page...
 
/lp/springer-journals/p2x7-a-growth-promoting-receptor-implications-for-cancer-pf9EhKJ5A9

References (39)

Publisher
Springer Journals
Copyright
Copyright © 2009 by Springer Science+Business Media B.V.
Subject
Biomedicine; Cancer Research ; Neurosciences ; Human Physiology ; Pharmacology/Toxicology ; Biomedicine general
ISSN
1573-9538
eISSN
1573-9546
DOI
10.1007/s11302-009-9145-3
pmid
19263244
Publisher site
See Article on Publisher Site

Abstract

The P2X7 receptor is widely referred to as the paradigmatic cytotoxic nucleotide receptor, and is often taken as an epitome of cytotoxic receptors as a whole. However, cytotoxicity is the result of sustained pharmacological stimulation, which is likely to occur in vivo only under severe pathological conditions. Over the years, we have gathered robust experimental proof that led us to adopt an entirely different view, pointing to P2X7 as a survival/growth-promoting rather than death-inducing receptor. Evidence in favour of this role is manifold: (1) extracellular ATP and benzoyl ATP support cell proliferation in peripheral T lymphocytes via a P2X7-like receptor; (2) P2X7 transfection into several cell lines confers growth advantage; (3) HEK293 cells transfected with P2X7 show enhanced mitochondrial metabolic activity and growth; (4) lipopolysaccharide (LPS)-dependent growth arrest of microglia is mediated via P2X7 down-modulation; (5) several malignant tumours express high P2X7 levels and (6) the ATP concentration in tumour interstitium is several-fold higher than in healthy tissues, to a level in principle sufficient to activate the P2X7 receptor. The molecular basis of P2X7-mediated growth-promoting activity is poorly known, but mitochondria appear to play a central role. A deeper understanding of the role played by P2X7 in cell proliferation might provide an insight into the mechanism of normal and malignant cell growth and suggest novel anti-tumour therapies.

Journal

Purinergic SignallingSpringer Journals

Published: Mar 4, 2009

There are no references for this article.